American Society of Hematology--50th Annual Meeting and Exposition--Part 2.
نویسندگان
چکیده
C, 20%; and imatinib 400 mg, 16% (P = 0.002). Optimal molecular deep and complete responses at 12 months also occurred more often in the imatinib/IFN arm (30%) than in the others: 15% with imatinib 400 mg, 18% with 600 mg, and 15% with 600 mg of imatinib + Ara-C (P = 0.0019). Higher rates of grade 3 and 4 toxicities, especially neutropenia and thrombocytopenia, were recorded with higher doses of imatinib and with the combination. Discontinuation of therapy was most frequent in the IFN arm (45%) at one year. The SPIRIT trial, Dr. Guilhot concluded, established the imatinib/PEG-IFN combination as the most efficacious therapy for chronic-phase CML.
منابع مشابه
Recent advances in the treatment of lymphoma.
A Review of Selected Presentations From the 49th American Society of Hematology Annual Meeting and Exposition, December 8-11, 2007, Atlanta, Georgia.
متن کاملAdvances in the treatment of myelodysplastic syndromes.
A Review of Selected Presentations From the 49th American Society of Hematology Annual Meeting and Exposition, December 8-11, 2007, Atlanta, Georgia.
متن کاملRecent advances in the treatment of T-cell lymphomas.
A Review of Selected Presentations From the 51st Annual Meeting and Exposition American Society of Hematology, December 5-8, 2009, New Orleans, Louisiana.
متن کاملAmerican Society of Hematology Annual Meeting and Exposition.
Key sessions on pharmacotherapy clinical trials across a wide span of disease states, including leukemia, graft-versus-host disease, myelofibrosis, multiple myeloma, and sickle cell disease, are reviewed.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- IDrugs : the investigational drugs journal
دوره 12 2 شماره
صفحات -
تاریخ انتشار 2009